Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec;47(6):2788-2799.
doi: 10.1007/s00266-023-03550-5. Epub 2023 Aug 14.

Injection Treatments for Vulvovaginal Atrophy of Menopause: A Systematic Review

Affiliations

Injection Treatments for Vulvovaginal Atrophy of Menopause: A Systematic Review

Felice Moccia et al. Aesthetic Plast Surg. 2023 Dec.

Abstract

Background: Injection treatments have been proposed as novel treatment options for Vulvovaginal Atrophy of Menopause (VVA) also known as Genitourinary Syndrome of Menopause (GSM). However, to date data about these treatments are poor.

Objective: To assess all available injection treatments for VVA.

Methods: A systematic review was performed by searching five electronic databases for peer-reviewed studies that assessed injection treatments for VVA.

Results: Eight studies (7 observational and 1 randomized) with 236 women were included. Assessed injection materials were: autologous platelet-rich plasma (PRP) + hyaluronic acid (HA), not cross-linked HA plus calcium hydroxyapatite (NCLHA + CaHA), micro-fragmented adipose tissue (MFAT), hyaluronan hybrid cooperative complexes (HCC), crosslinked HA, microfat and nanofat grafting + PRP, and PRP alone. Improvement in GSM symptoms after treatment was assessed through Visual Analogic Scale (VAS) for GSM symptoms or patient satisfaction, several validated questionnaires (FSFI, VHI, FSD, SF12, ICIQ UI SF, PGI-I, FSDS-R, VSQ), symptoms severity, changes in vaginal mucosa thickness, flora, pH, and expression on vaginal mucosal biopsies of Procollagen I and III and ki67 immunofluorescence or COL1A1 and COL3A1 mRNA. Injection treatments showing significant improvement in GSM-related symptoms were: (i) HCC in terms of VAS for GSM symptoms and FSFI score; (ii) Crosslinked HA in terms of VAS for GSM symptoms, FSFI and VHI score, COL1A1 and COL3A1 mRNA expression on vaginal mucosal biopsies; (iii) NCLHA + CaHA in terms of FSFI score; (iv) PRP + HA in terms of VHI, FSD and SF12 score; (v) microfat and nanofat grafting + PRP in terms of VHI score and FSDS-R score; (vi) PRP alone in terms of VHI and VSQ scores.

Conclusions: All assessed injection treatments except for MFAT seem to lead to significant improvement in VVA symptoms on validated questionnaires. Further studies are necessary in the field.

Level of evidence ii: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .

Keywords: Fat grafting; Genitourinary syndrome; Hyaluronic acid injection; PRP; Vulvar vaginal atrophy; Vulvovaginal laxity.

PubMed Disclaimer

References

    1. Portman DJ, Gass ML (2014) Vulvovaginal atrophy terminology consensus conference panel. Maturitas 79(3):349–354. https://doi.org/10.1016/j.maturitas.2014.07.013 - DOI - PubMed
    1. Mac Bride MB, Rhodes DJ, Shuster LT (2010) Vulvovaginal atrophy. Mayo Clin Proc 85:87–94. https://doi.org/10.4065/mcp.2009.0413 - DOI - PubMed - PMC
    1. Farrell E (2017) Genitourinary syndrome of menopause. Aust Fam Physician 46(7):481–484
    1. Reiter S (2013) Barriers to effective treatment of vaginal atrophy with local estrogen therapy. Int J Gen Med 6:153–158 - PubMed - PMC
    1. Levine KB, Williams RE, Hartmann KE (2008) Vulvovaginal atrophy is strongly associated with female sexual dysfunction among sexually active postmenopausal women. Menopause 15:661–666 - PubMed

Publication types

LinkOut - more resources